Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts
REY
0.028
154.5%
LIC
4.53
-35.7%
PFE
0.024
100%
LOC
0.12
-22.6%
VFX
0.002
100%
AKN
0.004
-20%
ICR
0.014
75%
CDE
0.024
-20%
AUK
0.003
50%
PNT
0.012
-20%
AYM
0.003
50%
ROG
0.004
-20%
DGR
0.007
40%
AQC
0.021
-19.2%
NGY
0.028
40%
RNT
0.026
-18.8%
PEC
0.015
36.4%
EVR
0.009
-18.2%
AS2
0.008
33.3%
OKJ
0.036
-18.2%
RGL
0.004
33.3%
BMM
0.047
-17.5%
WR1
0.185
27.6%
1AI
0.005
-16.7%
AMS
0.005
25%
SPX
0.005
-16.7%
D3E
0.225
25%
SIX
0.042
-16%
JLL
0.39
20%
TNY
0.11
-15.4%
OPL
0.025
19%
AON
0.006
-14.3%
TG6
0.16
18.5%
KGD
0.006
-14.3%
ZEU
0.02
17.6%
UNT
0.006
-14.3%
ILA
0.17
17.2%
SRL
0.895
-13.1%
VSR
0.014
16.7%
DAL
0.027
-12.9%
